Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity

Cancer Immunology, Immunotherapy

Volumn 56, Issue 12, 2007, Pages 1897-1910

  Kudo Saito, Chie ^a   Garnett, Charlie T ^a   Wansley, Elizabeth K ^a   Schlom, Jeffrey ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer immunotherapy; Costimulation; IL 2; Intratumoral; TCR avidity; TRICOM; Vaccination

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN; GLYCOPROTEIN GP 70; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; PROTEIN P53; RECOMBINANT INTERLEUKIN 2; RECOMBINANT VACCINE; TETRAMER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; FOWLPOX VIRUS; IMMUNE RESPONSE; LOW DRUG DOSE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE; TREATMENT DURATION; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FLOW CYTOMETRY; FOWLPOX; GENE THERAPY; GENETIC VECTORS; IMMUNE SYSTEM; IMMUNOTHERAPY; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; NEOPLASMS; T-LYMPHOCYTES;

EID: 34848861126     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0332-1     Document Type: Article

References (52)

1. Aarts WM, Schlom J, Hodge JW (2002) Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 62:5770
2. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW (2004) External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 64:4328
3. Chen B, Timiryasova TM, Andres ML, Kajioka EH, Dutta-Roy R, Gridley DS, Fodor I (2000) Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model. Cancer Gene Ther 7:1437
4. Dillman RO (1999) What to do with IL-2? Cancer Biother Radiopharm 14:423
5. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA (1996) Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88:202
6. Eades-Perner AM, van der Putten H, Hirth A, Thompson J, Neumaier M, von Kleist S, Zimmermann W (1994) Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res 54:4169
7. el-Shami K, Tirosh B, Bar-Haim E, Carmon L, Vadai E, Fridkin M, Feldman M, Eisenbach L (1999) MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol 29:3295
8. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM (2005) Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201:1591
9. Esquivel F, Yewdell J, Bennink J (1992) RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes. J Exp Med 175:163
10. Evans DE, Weinberg AD (2003) Boosting T cell costimulation in cancer: the possibilities seem endless. Int Rev Immunol 22:173
11. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688
12. Galanis E, Burch PA, Richardson RL, Lewis B, Pitot HC, Frytak S, Spier C, Akporiaye ET, Peethambaram PP, Kaur JS, Okuno SH, Unni KK, Rubin J (2004) Intratumoral administration of a 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma. Cancer 101:2557
13. Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron N, Brasseur F, Lethe B, De Plaen E, Velu T, Boon T, Coulie PG (2005) High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201:241
14. Greiner JW, Zeytin H, Anver MR, Schlom J (2002) Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 62:6944
15. Zarour HM, Zarour AD, Finn OJ, Storkus W (2003) Tumor antigens. In: Kufe DW (ed) Cancer medicine. BC Decker Inc, Hamilton, p 195
16. Hersh EM, Stopeck AT (1997) Advances in the biological therapy and gene therapy of malignant disease. Clin Cancer Res 3:2623
17. Hilburger Ryan M, Abrams SI (2001) Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant. Cancer Immunol Immunother 49:603
18. Hodge JW, McLaughlin JP, Kantor JA, Schlom J (1997) Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15:759
19. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J (1999) A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 59:5800
20. Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J (2003) Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res 9:1837
21. Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, Robinson BW, Nelson DJ (2003) IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol 171:5051
22. Jourdier TM, Moste C, Bonnet MC, Delisle F, Tafani JP, Devauchelle P, Tartaglia J, Moingeon P (2003) Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). Gene Ther 10:2126
23. Kalus RM, Kantor JA, Gritz L, Gomez Yafal A, Mazzara GP, Schlom J, Hodge JW (1999) The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation. Vaccine 17:893
24. Kass E, Parker J, Schlom J, Greiner JW (2000) Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen-presenting cells in regional lymph nodes. Cytokine 12:960
25. Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW (1999) Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 59:676
26. Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW (2001) Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 61:206
27. Kielian T, Nagai E, Ikubo A, Rasmussen CA, Suzuki T (1999) Granulocyte/macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1alpha and accumulation of dendritic cells at vaccination sites in vivo. Cancer Immunol Immunother 48:123
28. Kudo-Saito C, Schlom J, Hodge JW (2004) Intratumoral vaccination and diversified subcutaneous/intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules. Clin Cancer Res 10:1090
29. Kudo-Saito C, Schlom J, Camphausen K, Coleman CN, Hodge JW (2005) The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin Cancer Res 11:4533
30. Kudo-Saito C, Schlom J, Hodge JW (2005) Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res 11:2416
31. Lacabanne V, Viguier M, Guillet JG, Choppin J (1996) A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells. Eur J Immunol 26:2635
32. Liu K, Abrams SI (2003) Alterations in Fas expression are characteristic of, but not solely responsible for, enhanced metastatic competence. J Immunol 170:5973
33. Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P (2004) Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 101(Suppl 2):14567
34. Maloy KJ, Powrie F (2005) Fueling regulation: IL-2 keeps CD4+ Treg cells fit. Nat Immunol 6:1071
35. McKee MD, Roszkowski JJ, Nishimura MI (2005) T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med 3:35
36. McLaughlin JP, Schlom J, Kantor JA, Greiner JW (1996) Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res 56:2361
37. Morse MA (2001) Technology evaluation: CEA-TRICOM, Therion Biologics Corp. Curr Opin Mol Ther 3:407
38. Moss B (1996) Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 93:11341
39. Murphy WJ, Welniak L, Back T, Hixon J, Subleski J, Seki N, Wigginton JM, Wilson SE, Blazar BR, Malyguine AM, Sayers TJ, Wiltrout RH (2003) Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol 170:2727
40. Pantuck AJ, van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, Ross ME, Belldegrun AS, Figlin RA (2004) Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother 27:240
41. Pilon SA, Kelly C, Wei WZ (2003) Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor. J Immunol 170:1202
42. Qin H, Valentino J, Manna S, Tripathi PK, Bhattacharya-Chatterjee M, Foon KA, O'Malley BW Jr, Chatterjee SK (2001) Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression. Mol Ther 4:551
43. Robbins PF, Kantor JA, Salgaller M, Hand PH, Fernsten PD, Schlom J (1991) Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 51:3657
44. Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, Tartour E, Zhao Y, Bizouarne N, Baudin M, Acres B (2003) Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 5:690
45. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. Jama 271:907
46. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, Gritz L, Panicali DL, White DE (2003) Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res 9:2973
47. Scholl S, Squiban P, Bizouarne N, Baudin M, Acres B, Von Mensdorff-Pouilly S, Shearer M, Beuzeboc P, Van Belle S, Uzielly B, Pouillart P, Taylor-Papadimitriou J, Miles D (2003) Metastatic breast tumour regression following treatment by a gene-modified vaccinia virus expressing MUC1 and IL-2. J Biomed Biotechnol 2003:194
48. Sivanandham M, Scoggin SD, Tanaka N, Wallack MK (1994) Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model. Cancer Immunol Immunother 38:259
49. Snyder JT, Alexander-Miller MA, Berzofskyl JA, Belyakov IM (2003) Molecular mechanisms and biological significance of CTL avidity. Curr HIV Res 1:287
50. Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrout RH (1996) Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 88:38
51. Yang JC, Perry-Lalley D (2000) The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors. J Immunother 23:177
52. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127